Garon EB, Hellmann MD, Costa EC, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. ASCO Annual Meeting 2019, abstract LBA9015.
Nab-paclitaxel plus gemcitabine en cisplatine bij gevorderd adenocarcinoom van de pancreas
jan 2020 | Maag-darm-leveroncologie